We aim to advance ADP-520 to clinical study with an eye towards developing a first-in-class autologous and armored CD70-targeted cell immunotherapy for addressing the unmet needs of both hematologic malignancies and solid tumors, such as RCC. This evidence concerns the gene CD70 and renal cell carcinoma.